News|Articles|March 6, 2026

7 Allergy Headlines You Missed in February 2026

Fact checked by: Tim Smith

This month in review features 7 allergy headlines in February 2026: FDA's decision on Dupilumab for AFRS, late-breaking data presented at AAAAI, & more.

February 2026 brought several notable developments across allergy and immunology, spanning regulatory decisions, updated clinical guidance, and emerging research presented at the 2026 American Academy of Allergy, Asthma, & Immunology annual meeting in Philadelphia from February 27 to March 2. From the US Food and Drug Administration (FDA) approval of dupilumab for allergic fungal rhinosinusitis to a Complete Response Letter for dibutepinephrine (Anaphylm), the month reflected both progress and ongoing hurdles in therapeutic development.